Relationships between pharmacokinetics, antiemetic effect and adverse effect of prochlorperazine

Relationships between pharmacokinetics, antiemetic effect and adverse effect of prochlorperazine - Relationships between pharmacokinetics, antiemetic effect and adverse effect of prochlorperazine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011323

Enrollment

100

Registered

2013-07-31

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients receiving oral prochlorperazine for the prevention of opioid-induced nausea and vomiting

Exclusion criteria

Exclusion criteria: Patients who (1) discontinued oral prochlorperazine or opioid analgesics during the study; (2) were being co-treated with anticancer drugs; (3) were being co-treated with other dopamine receptor D2 antagonists; (4) were being co-treated with triazole antifungal agents, rifampin, or macrolide antibiotics; (5) were diagnosed as having prolactin-producing adenoma or brain tumors; and (6) were difficult to evaluate with respect to nausea and vomiting.

Design outcomes

Primary

Measure	Time frame
Impact of plasma prochlorperazine concentrations and gene polymorphisms on antiemetic effect and serum prolactin level	—

Countries

Japan

Contacts

Public ContactMasaki Tashiro

Hamamatsu University School of Medicine Department of Hospital Pharmacy

Outcome results